Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chelsea reports progress in Phase II arthritis trial
To date, Chelsea has enrolled 147 of the planned 200 patients for this 12-week, four-arm, parallel group trial comparing 0.25mg, 0.5mg and 1mg once daily oral doses of
To date, Chelsea has enrolled 147 of the planned 200 patients for this 12-week, four-arm, parallel group trial comparing 0.25mg, 0.5mg and 1mg once daily oral doses of
Under the terms of the agreement, clinical researchers from University of California, San Diego (UCSD) will perform the Phase IIa study at the University’s General Clinical Research Center,
Dr Goldberg previously served as president of clinical research services and perceptive informatics at Parexel. Dr Goldberg will continue to oversee these areas of the company and report
As part of the transaction, a subsidiary of Brookfield Asset Management the holder of approximately 60% of the outstanding common shares of MediSolution has entered into an agreement
The company has agreed to sell 1.13 million shares of common stock and the selling stockholders have agreed to sell the remaining 2.36 million shares of common stock.
The Phase II, double-blinded placebo controlled 12-week dosing trial will enroll approximately 90 patients who are stable on metformin treatment only, the current first-line therapy for type 2
Following validation by Proteome Systems of data generated by Egenix, which demonstrated increased expression of HCA (human carcinoma antigen) in cancerous versus non-cancerous prostate tissues, the proof of
Previously, BioSante received a special protocol assessment (SPA) for LibiGel’s use in ‘surgically’ menopausal women. Stephen Simes, BioSante’s president & CEO, said: “With our two SPAs and meeting
PTC will receive up to $25 million from Cystic Fibrosis Foundation Therapeutics in support of key Phase IIb clinical trials for PTC124 in cystic fibrosis (CF). Stuart Peltz,
This is the second milestone reached in the three-year collaboration initially announced in January 2006. In the collaboration, BioFocus DPI applied its SilenceSelect shRNA-based gene collection to run